Abbott Laboratories vs GE HealthCare
Abbott Laboratories is the larger business, with $44.33bn of revenue in fiscal 2025 against $20.63bn for GE HealthCare (2.1 times as much). Abbott Laboratories grew faster (5.7% against 4.8%). Abbott Laboratories kept more of each dollar of sales as profit: a net margin of 14.7% against 10.1%. Abbott Laboratories carries less debt relative to equity (24.8% against 101.3%).
| Latest fiscal year | Abbott LaboratoriesABT, 2025 | GE HealthCareGEHC, 2025 |
|---|---|---|
| Revenue | $44.33bn | $20.63bn |
| Revenue growth | 5.7% | 4.8% |
| Net income | $6.52bn | $2.08bn |
| Operating margin | 18.2% | 13.4% |
| Net margin | 14.7% | 10.1% |
| Return on equity | 13.1% | 22.1% |
| Free cash flow | $7.39bn | $1.50bn |
| Cash | $8.52bn | $4.49bn |
| Total debt | $12.93bn | $10.51bn |
| Debt to equity | 24.8% | 101.3% |
| Dividend per share | $2.40 | $0.14 |
| Dividend yield | 2.2% | 0.2% |
| Share buybacks | $893m | $200m |
| Employees | 115,000 | 54,000 |
| Market value | $190.32bn | $36.36bn |
| Price vs our value range | Above our value range | Above our value range |
| Moat score | 72 (Strong) | — |
| Insider trades, 12 months | 6 buys, 11 sales | 8 buys, 0 sales |